Abstracts
1
Comenius University, Faculty of Social and Economic Sciences, Bratislava, Slovak Republic, 2 Comenius University, Faculty of Pharmacy, Bratislava, Slovak Republic OBJECTIVES: Experience indicated that the quality of economic evaluations submitted in reimbursement dossiers and critical appraisals are heterogeneous. The objective of this study was to analyse the quality of submitted economic studies and related critical appraisal processes and to develop a policy-relevant, publicly available Slovak critical appraisal checklist for improving the quality of economic evaluation and budget impact analyses for reimbursement submission of dossiers concerning to drugs and medical devices. METHODS: We created a working group to review previously submitted economic evaluations and related critical appraisals in order to identify potential technical and methodological problems. The working group consisted of independent academic experts who scrutinized previous submissions and critical appraisals and developed a new checklist. Overall 50 economic evaluations submitted for reimbursement of drugs and medical devices in 2007-2009 were scrutinized. RESULTS: Evidence suggests that Slovak pharmaceutical expenditures do not result in the most cost-effective outcomes. Several potentially not cost-effective pharmaceuticals have been reimbursed in Slovakia. Economic evaluations of drugs and medical devices are mandatory but the quality of evaluations and critical appraisals are rather poor. Therefore in addition to the available Slovak health economic evaluation guidelines a detailed checklist for appraisal processes have to be prepared. Our analysis shows that the simplified questionnaire, which is currently used for the critical appraisal process within Slovakia should be replaced by a new Slovak critical appraisal checklist, which will be detailed enough to address the most common problems in the local economic evaluations and budget impact analyses for decision making process.
CONCLUSIONS:
The transparent method of technology assessment can improve the consistency of reimbursement decisions making related to drugs and medical devices in Slovakia. The current checklist for critical appraisal is not sufficient enough and there is significant room for improvement in this field.
PHP84 OUTCOMES OF BEDSIDE-BARCODE TECHNOLOGY INTERVENTION ON MEDICATION ADMINISTRATION TIME IN AN INTENSIVE CARE UNIT
Sansgiry S 1 , Dwibedi N 1 , Frost C 2 , Dasgupta A 3 , Doan T 1 , Johnson M 1 , Tipton J 4 , Jacob S 2 , Schanafelt C 2 , Shippy A 2 1 University of Houston, Houston, TX, USA, 2 St. Luke's Episcopal Hospital, Houston, TX, USA, 3 The University of Texas at Austin, Austin, TX, USA, 4 Baylor College of Medicine, Houston, TX, USA OBJECTIVES: The objective of this study was to evaluate outcomes of a bedside barcode technology intervention on medication administration time in an intensive care unit (ICU). METHODS: A prospective observational time-and-motion experimental study was conducted by considering two medication administration processes (a paper based approach vs. the bedside barcode system) in a large 500+ bed hospital setting. Medication administration by the nurse was operationalized as activities such as direct or indirect patient care, administration, and miscellaneous. Time devoted to complete these medication administration activities were measured separately by means of two pre-calibrated stop watches. Complexity factors of medication administration (age, sex, body-weight, comorbidities, number of drugs administered, and length of ICU stay) were included in linear regression model to predict time required for each of those medication administration activities. RESULTS: One hundred and fifty-one electronically documented medication administrations with the bedside barcode system were evaluated Mean times of direct patient care activity (182.32 ± 131.68 seconds) and administration activity (59.83 ± 74.53 seconds) during bedside barcode medication administration improved significantly in comparison with paper based approach. In the bedside barcode system, significant (p < 0.05) predictors of time associated with direct patient care activity was number of drugs administered, for indirect patient care activity was comorbidities, and for administration activity was length of ICU stay. CONCLUSIONS: Variables that predict medication administration time in the bedside barcode system were different across the categorized activities. To develop and implement efficient systems, such variables should be monitored and controlled as high cost technology is adopted by hospitals. Force. Seventeen interviews of health plan executives were used to identify whether and how these frameworks were used in policy decisions made by individual plans. A meeting that included interviewees and other thought leaders was used to discuss similarities and differences across payers in whether and how formal evaluations informed policy. The study focused on personalized medicine, the use of genetics or genomics to guide health care decisions. RESULTS: We found that frameworks vary in: purpose, questions of interest, range of evidence included, availability, and capacity. All frameworks were used by at least one payer to inform policy decisions with one framework (BCBS TEC) used by all but one interviewed payer. All payers reported using multiple frameworks. Payers reported key gaps in frameworks including: lack of evidence on health care system factors, lack of timeliness and lack of breadth. Across payers the range of evidence used to inform decisions was believed to result in policy variation. In particular, when clinical evidence is uncertain but decisions needed, payers reported using nonclincal evidence to help guide decisions. CONCLU-SIONS: Payers use evidence reviews to inform policy decisions but no single framework is sufficient. Key ways to improve reviews for insurance policy decisions might focus on balancing the tension between comprehensiveness and timeliness. technologies (e.g., pharmaceuticals, medical devices, and diagnostics) with respect to cost and their projected impact on patient outcomes and society. Currently, there is an ongoing initiative by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) to develop Road Maps that describe the utilization of HTA in health care. The purpose of this study was to develop models for HTA decisionmaking structures along with reimbursement road maps for several countries. METHODS: Members of the ISPOR Special Interest Group (SIG) for HTA contacted key individuals in several countries, including: Austria, Demark, Hungary, Ireland, France, Germany, Denmark, UK, Sweden, Australia, Canada, Taiwan, United States, and others. Once decision models and corresponding reimbursement road maps were developed within designated HTA subgroups, the information was disseminated to all HTA committee members for review. After review, the decision models were sent to key stakeholders in each selected country for review and validation. RESULTS: Decision-making structures and review processes for reimbursement were developed for the selected counties. Key decision makers and/or third-party payers (e.g., person or organization) were identified and defined in accordance with their role in the reimbursement process. Evaluators were defined as individuals or organizations that provide input into the decision-making process regarding HTA development, but may not be responsible for final coverage and payment decisions. CONCLUSIONS: Decision structures for reimbursement (e.g., coverage, coding, and payment) vary according to the type of product (e.g., pharmaceutical, medical device, and diagnostic), the individual country and in some instances, by regions within the country. The HTA-SIG will continue to identify and validate HTA decision pathways for reimbursement within each country to provide guidance to manufacturers and policy makers in a way that optimizes efficiencies and supports the ongoing societal needs for access to emerging technologies.
PHP85

PHP86 DEVELOPING GLOBAL ROAD MAPS FOR REIMBURSEMENT PROCESSES USED IN HEALTH TECHNOLOGY ASSESSMENT: PHARMACEUTICALS, MEDICAL DEVICES, AND DIAGNOSTICS
PHP87 DECISION CRITERIA FOR TECHNOLOGY ACQUISITION IN RADIOONCOLOGY-WHAT REALLY MATTERS?
Gurtner S 1 , Uecke O 2 , Schefczyk M 1 1 Technische Universität Dresden, Dresden, Sachsen, Germany, 2 Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Sachsen, Germany OBJECTIVES: The assessment of medical technologies in hospitals is often an unstructured not transparent process, only involving a small group of decision makers. To overcome barriers while discussing or implementing decisions, a clear communication of how technologies are chosen is essential. The decision criteria and its weights should represent the management's as well as the potential user's perspective of the technology. METHODS: To identify relevant criteria in terms of technology acquisition, a literature review was carried out. As a second step 221 HTA-experts were confronted with the ten most frequent criteria, with the task to evaluate their importance and to supplement them. To evaluate the individual weight of each criterion a survey was conducted, including three relevant user groups within the sector of radiooncology. For each of the 115 recipients and an overall preference profile was calculated using an AHP-model. The influence of factors such as job, leadership, sex, user, size of hospital and typ of hospital were also analyzed using an analysis of variance. RESULTS: As result of step one and two the following seven criteria were identified: effectiveness, the need for treatment, patient preferences, usability, cost-effectiveness, organizational impact, budget impact. The overall AHP-model identified the organizational impact (16.9%) as the most relevant criterion, followed by the budget impact (15.7%). The variance analysis showed that all factors, except the size of the hospital influence certain criteria of the preference profile in a significant way. CONCLU-SIONS: Surprisingly, the organizational impact is the most important criterion directly followed by the budget impact. The organizational impact is today often underestimated. Therefore, organizational barriers exist and can delay or hinder innovation. To determine essential characteristics of a new technology and to lower barriers regarding its acceptance, the preferences of each group should be evaluated and integrated in decisions. The purpose of this study is to better understand the types of evidence considered and how evidence is used by health care payers and payer intermediary organizations to evaluate prescription drugs and biologics for possible formulary inclusion. METHODS: We conducted semi-structured one-hour telephone interviews with key decision makers at payers and payer intermediary organizations. Respondents included medical and pharmacy directors who actively participate in pharmaceutical technology assessment (PTA). Participants were asked to describe their PTA process and to rate the importance of the sources and types of evidence they review. RESULTS: Pharmacy and medical directors from 15 national and regional health plans, prescription drug plans, and pharmacy benefit managers rated information used for PTA on a scale of 1 (not important) to 5 (very important). While preliminary results indicate that respondents rated peer-reviewed studies as the most important source of information (mean = 4.7), technology assessments such as comparative effectiveness studies (e.g., from AHRQ or Hayes) and internal (health plan) data on utilization were rated almost as highly (4.2 and 4.1, respectively). Medical directors gave comparative effectiveness studies higher ratings than did pharmacy directors (4.7 vs. 3.8; p < 0.001). Among types of evidence, randomized control trials (RCTs) were rated the highest (mean = 4.6); budget impact analyses (mean = 3.1) and pharmacoeconomic studies (mean = 2.9) had substantially lower rating, although both of these received higher ratings from pharmacy vs. medical directors. There was little variation in ratings by payer type. CONCLUSIONS: While it is not surprising that key decision makers highly value RCTs from peer-review literature, other sources of information were rated as having essentially the same importance. Medical and pharmacy directors have significant differences in the importance assigned to certain information. Additional data will help to explore variations in perceived value of information among different types of PTA staff and potentially differences across payer types.
PHP88 EVIDENCE USED DURING PHARMACEUTICAL TECHNOLOGY ASSESSMENT
PHP89 THE INFLUENCE OF SAFETY ISSUES ON DECISIONS OF CONSULTATIVE COUNCIL OF THE AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND
Agency for Health Technology Assessment in Poland, Warsaw, Poland, 2 Agency for Health Technology Assessment in Poland, Warsaw, Poland OBJECTIVES: Consultative Council (CC) is an independent body playing a central role in decision making of Polish Heath Technology Assessment Agency (AHTAPol). We were interested in how much safety issues of the appraised technologies concern members of CC and what is the influence of safety issues on CC's decisions. METHODS: We analyzed decisions of CC published until the end of 2009 and distinguish those where safety issues were significant arguments for decline. We indentify the type of key documents quotabled in the decisions in order confront them with documents included in manufacturer's HTA reports. RESULTS: Among 148 CC's decisions analyzed, 70 were negative and in 22 safety issues were significant arguments against the positive recommendation (31% of all negative decisions). Apart of the manufacturer's HTA reports, CC based mainly on EMEA or national Summary Of Product Characteristics (91%), FDA reports and Cochrane reviews (23% each), RCT not included in the submission (17%) and non-systematic reviews (13%). Manufacturer's HTA reports on safety included mainly III phase RCTs (77%), II phase RCTs (36%), observational studies (27%), systematic (non-Cochrane) or non-systematic reviews (9%). Seldom, if ever, submitted reports mentioned FDA or EMEA reports and patient registries (5%). CONCLUSIONS: Safety issues were important argument in negative opinions of CC. Unlike efficacy, safety analysis comprise evidence other than III phase RCTs. Manufacturer's HTA reports did not cover many documents significant to CC regarding safety. A wider safety analysis according to the ATHAPol's guidelines 2009 would be required.
HEALTH CARE USE & POLICY STUDIES -Patient Registries & Post-Marketing Studies
PHP90 A DESCRIPTIVE STUDY OF PATIENTS ON FDA-CATEGORIZED INNOVATIVE DRUGS IN ANTICHOLESTEROL AND ANTIDIABETIC THERAPEUTIC CLASSES
Basak RS, Padwal T University of Mississippi, University, MS, USA OBJECTIVES: Drugs receive priority (P) or standard (S) review based on FDA's perceptions that the drug offers significant benefit over existing options. The study will describe patient characteristics associated with drugs that got P and S approval. METHODS: This pilot study employed a retrospective cohort design using MEPS data (full year consolidated, prescription medicine, and medical condition files) from [2004] [2005] [2006] [2007] . Subjects were identified from the prescription medicine files if they received P drugs (atorvastatin, pioglitazone, rosiglitazone, repaglinide) or S drugs (simvastatin, pravastatin, rosuvastatin, glimepiride, exenatide, sitagliptin). All other drugs that were received by these subjects and approved 1990 onwards were coded for their approval status from the FDA website. Subjects in the S group receiving any P drug or who received the aforementioned drugs from both groups were excluded. Variables at the year subjects entered the MEPS were analyzed. RESULTS: A total of 5835 patients-3810 patients on one or more P drugs and 2025 on S drugs-were identified. There was no significant difference of age of the patients in these groups. Patients' race and gender (Asian vs. White OR = 1.556; female vs. male OR = 1.367) was associated (p < 0.05) with odds of receiving priority drugs. Patients receiving P drugs had significantly (p < 0.05) higher number of comorbidities compared to those in the S group. Respiratory diseases, endocrine disorders, tumor, hypertension, and number of comorbidities were significant (p < 0.05) predictors of receiving P drugs. Patients in the P group reported significantly (p < 0.05) poorer health status. However, when adjusted with propensity score such difference was not associated with the drug categories. CONCLUSIONS: Patient demographics was associated with receiving antidiabetic and anticholesterol therapeutic classes of drugs that received priority review. After controlling for comorbidities, number of comorbidities was positively associated with likelihood of receiving P drugs. When adjusted for covariates, such categorization was not associated with self-reported health status.
HEALTH CARE USE & POLICY STUDIES -Prescribing Behavior & Treatment Guidelines
PHP91 DRUGS PRESCRIBING INDICATORS IN SECOND AND THIRD-LEVEL COMPLEXITY HOSPITALS FROM COLOMBIA
Buendia Rodriguez JA, Garcia Vega OA Universidad Nacional de Colombia, Bogota, Colombia OBJECTIVES: To evaluate drugs prescribing indicators of outpatient medication in medium-and high-level complexity hospitals from Colombia METHODS: This was a cross-sectional study where medication prescription was evaluated in 331 secondand third-level complexity hospitals from 27 Colombian departments during 2006-2007 RESULTS: 38863 prescriptions for 3663 patients were analyzed; 54.7% of them patients affiliated to contributory health care system. Average prescribed medication per person was 2,2 (2,1-2,2 95 % CI), the percentage of antibiotics formulated by prescription was 29,2 % (28,7-29,6 95 % CI), essential prescribed medicines accounted for 64,2 % (63,7-64,6 95 % CI) and injectable medicines was 22,1 % (21,7-25,5 %). More than half the medications (62,1 %; 61,5-62,7 95 % CI) were in three ATC groups (anti-infectious agents, immunomodulating agents and medications for the alimentary and metabolic tract). DU90% consisted of 64 medications and the medication consumption was of 8, 39 daily defined doses (DDD)/1000 patients CONCLUSIONS: Respect to previous studies in Colombia the indicators remain with few change, except the percentage of antibiotics formulated by prescription that increased more than recommended by OMS (25%). This is the first report of DU90% and DDD in Colombian patients and these indicators must be continuously evaluated in future to follow the quality of prescription and drug consumption.
PHP92 HEALTH CARE PROFESSIONAL STUDENTS' KNOWLEDGE OF DRUG-DRUG INTERACTIONS: A PRETEST POSTTEST STUDY
Harrington AR 1 , Warholak TL 1 , Malone D 2 1 The University of Arizona, Tucson, AZ, USA, 2 University of Arizona, Tucson, AZ, USA OBJECTIVES: To evaluate the knowledge change among medical, pharmacy, and nurse practitioner students after attending a drug-drug interaction (DDI) educational program. METHODS: Students were given a DDI knowledge assessment containing 15 drug pairs. They were asked to assess each drug pair and select the corresponding appropriate management strategy. Following the knowledge assessment, students attended a 45-minute training program during which all 15 drug pairs were addressed. The first outcome of interest was "Management Strategy," where students were given credit only if they selected the correct management strategy. Actions included "Avoid
